These analyses also showed high expression of the other novel BenSer target transporters (Fig. 4d-h, and two other LAT family transporters (LAT3/SLC43A1, LAT4/SLC43A2; Additional file 2: Figure S2C-D), but with little difference in expression across genetic subtypes (“PAM50 classification plus claudin-low”), suggesting that upregulation of these transporters occurs non-specifically in breast cancer and that therapies designed to target these pathways could have broad efficacy across clinical subgroups. This evidence concerns the gene SLC43A2 and breast carcinoma.